Evidence map›Paper›PMID 41160462›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Brain region-specific dopamine receptor changes and astrocyte activation influence tau pathology through CDK5 in Alzheimer's disease models.

Sneha Singh, Ujendra Kumar

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sneha SinghFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
Ujendra KumarFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundThe abnormal extracellular accumulation of amyloid-β (Aβ) plaques and intracellular tau inclusions are hallmarks of early events in the pathogenesis of Alzheimer's disease (AD). Although growing evidence implicates neurotransmitter dysregulation in AD-associated neurodegeneration, the influence of these pathological hallmarks on dopaminergic signaling remains poorly understood. This study reports changes in dopamine receptor (DR), Aβ, and astrocyte distribution in the cortex and hippocampus of 5XFAD mice.ObjectiveTo investigate how Aβ pathology alters dopamine receptor subtype expression in the AD brain and neuronal models, and whether this contributes to tau phosphorylation and CDK5 activation.MethodsWe examined DR1-DR5 expression and localization in the cortex and hippocampus of 5XFAD mice using immunohistochemistry, qPCR, and western blot. SH-SY5Y cells were differentiated with retinoic acid and treated with Aβ

Indexed as

Alzheimer DiseaseAstrocytesBrainCyclin-Dependent Kinase 5Receptors, Dopaminetau ProteinsAmyloid beta-PeptidesAnimalsCell Line, TumorDisease Models, AnimalHippocampusHumansMaleMiceMice, TransgenicPhosphorylationAmyloid beta-PeptidesCdk5 protein, mouseCyclin-Dependent Kinase 5Receptors, Dopaminetau ProteinsAlzheimer's diseasecAMP signalingCDK5dopamine receptorsneuroinflammationtau phosphorylation

Identifiers

PMID41160462
PMCPMC12664925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.